However, the above statistics show that it is not less frequent in other epithelial cancer types, and MET amplification is one of the frequent aquired alterations (5–20% of patients) upon resistance towards EGFR tyrosine kinase inhibitor (TKI) therapies in lung cancer [39]. This evidence concerns the gene EGFR and lung carcinoma.